Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA/EU Mutual Reliance For GMP Inspections Moving Forward

This article was originally published in The Pink Sheet Daily

Executive Summary

Both sides may agree to overlook “areas of divergence” if they don’t appear significant.

You may also be interested in...



FDA Piloting Oncology Supplement Review Using Only Data Summaries

Advantages could be shorter review times and expanded labels, but there are concerns about no global regulator having access to full patient-level data.

FDA Piloting Oncology Supplement Review Using Only Data Summaries

Advantages could be shorter review times and expanded labels, but there are concerns about no global regulator having access to full patient-level data.

FDA Launches Global Rx Quality Initiative With Plans To Rely On Non-U.S. Regulators

Agency restructures staff as it prepares for new U.S.-EU mutual reliance activities to enhance pharmaceutical quality but offers few details on upcoming plans.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS077705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel